PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
24.06%
Net income growth exceeding 1.5x Medical - Pharmaceuticals median of 1.51%. Joel Greenblatt would see it as a clear outperformance relative to peers.
11.18%
D&A growth of 11.18% while Medical - Pharmaceuticals median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
533.47%
Working capital of 533.47% while Medical - Pharmaceuticals median is zero at 0.00%. Walter Schloss would check if expansions or cost inefficiencies cause that difference.
No Data
No Data available this quarter, please select a different quarter.
-257.30%
Inventory shrinks yoy while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a working capital edge if sales hold up.
No Data
No Data available this quarter, please select a different quarter.
461.02%
Growth of 461.02% while Medical - Pharmaceuticals median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.
132.07%
Under 50% of Medical - Pharmaceuticals median of 25.05% if negative or well above if positive. Jim Chanos would flag potential major accounting illusions or revaluations overshadowing underlying performance.
3653.82%
CFO growth of 3653.82% while Medical - Pharmaceuticals median is zero at 0.00%. Walter Schloss would see a small edge that may compound with consistent execution.
2.20%
CapEx growth of 2.20% while Medical - Pharmaceuticals median is zero at 0.00%. Walter Schloss would question expansions or upgrades behind the difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-79.93%
We reduce “other investing” yoy while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a potential advantage in preserving cash if top-line growth is not harmed.
-10.57%
Reduced investing yoy while Medical - Pharmaceuticals median is 0.00%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.
-0.44%
Debt repayment yoy declines while Medical - Pharmaceuticals median is 0.00%. Seth Klarman fears increased leverage if expansions do not yield quick returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.